CD8A and neoplasm: These results support continued evaluation of Vidu as a cancer immunotherapeutic agent, including in combination with immune checkpoint blockade.<h4>Significance</h4>In situ immunization with Vidu combined with αPD-1 therapy enhances the antitumor response by tumor-specific CD8+ T cells by expanding the systemic and intratumoral populations.